Table 2.
Participants’ characteristics of included studies.
| Study | Years | Sample (n) |
Smoking habits (n) (current/never/former) | Age (y) | KL-6 |
|---|---|---|---|---|---|
| HP | HP | HP | HP | ||
| Controls | Controls | Controls | Controls | ||
| d'Alessandro M | 2020 | 34 | 0/14/20 | 65 ± 9.5 | 1691 ± 1643 U/ml |
| 22 | 0/17/5 | 54 ± 14.9 | 268 ± 148 U/ml | ||
| d'Alessandro M | 2021 | 14 | 0/6/8 | 65.2 ± 12.3 | 1047.7 ± 308.1 U/ml |
| 12 | 0/8/4 | 65.2 ± 12.3 | 189 ± 100.6 U/ml | ||
| Ding YJ | 2018 | 37 | NA | 60.9 ± 6.4 | 1801.26 ± 185.36 U/ml |
| 35 | NA | 60.8 ± 6.4 | 201.17 ± 20.37 U/ml | ||
| He XB | 2005 | 16 | NA | 62.3 ± 11.7 | 1218 ± 647 U/ml |
| 20 | NA | 60.5 ± 10.3 | 247 ± 120 U/ml | ||
| Janssen R | 2005 | 49 | 2/21/26 | 56 ± 12 | 1396.6 ± 894.2 U/ml |
| 38 | 0/27/11 | 46 ± 14 | 207 ± 66 U/ml | ||
| Ji Y2020 | 2020 | 20 | NA | 49.8 ± 15.1 | 818.4 ± 674.9 U/ml |
| 10 | NA | NA | 266.6 ± 194.3 U/ml | ||
| McSharry CP | 2006 | 55 | 0/55/0 | 53.5 ± 7.9 | 511.7 ± 261.8μg/mL |
| 15 | 0/15/0 | 49.3 ± 4.4 | 296.9 ± 230.6μg/mL | ||
| Mostafa AI(fHP) | 2021 | 27 | NA | NA | 1,165.00 ± 283.0 IU/ml |
| 20 | NA | NA | 138.2 ± 69.5 IU/ml | ||
| Mostafa AI(nfHP) | 2021 | 24 | NA | NA | 2020.83 ± 870.77 IU/ml |
| 20 | NA | NA | 138.2 ± 69.5 IU/ml | ||
| Mostafa AI(Bird-HP) | 2021 | 35 | NA | NA | 1644.43 ± 835.71 IU/ml |
| 20 | NA | NA | 138.2 ± 69.5 IU/ml | ||
| Nukui Y | 2019 | 61 | NA | 63.8 ± 11 | 1236 ± 1072.8 U/ml |
| 50 | NA | 47.3 ± 9.9 | 191 ± 70.2 U/ml | ||
| Okamoto T * | 2015 | 35 | 19/13/3 | 58.6 ±15.4 | 3350 ± 3246 U/ml |
| 57 | 26/20/11 | 61.3 ± 9.9 | 1639.9 ± 1250.3 U/ml | ||
| Ren DH | 2015 | 149 | NA | 58.8 ± 11.7 | 1801.86 ± 2831.36 U/ml |
| 64 | NA | 39 ± 13.9 | 201.28 ± 81.18 U/ml | ||
| Silvia Sánchez-Díez (Bird -HP) | 2022 | 24 | NA | NA | 2805.6 ± 5346.9 U/ml |
| (fHP and Bird -HP) | 67 | 0/0/67 | NA | 283.7 ± 282.6 U/ml | |
| Silvia Sánchez-Díez (Fungi-HP) | 2022 | 10 | NA | NA | 1590.3 ± 2604.1 U/ml |
| (fHP and Fungi-HP) | 67 | 0/0/67 | NA | 283.7 ± 282.6 U/ml | |
| Silvia Sánchez-Díez (fHP) | 2022 | 8 | NA | NA | 1298.7 ± 2164.1 U/ml |
| (nfHP and Bird-HP) | 67 | 0/0/67 | NA | 283.7 ± 282.6 U/ml | |
| Silvia Sánchez-Díez (nfHP) | 2022 | 7 | NA | NA | 1075.6 ± 1996.0 U/ml |
| (nfHP and Fungi-HP) | 67 | 0/0/67 | NA | 283.7 ± 282.6 U/ml | |
| Takahashi T | 2000 | 5 | NA | NA | 1263 ± 644 U/ml |
| 237 | NA | NA | 207 ± 92.37 U/ml | ||
| Tsushima K | 2005 | 4 | NA | NA | 981 ± 331 U/ml |
| 22 | 0/22/0 | 49.2 ± 7 | 251 ± 68 U/ml | ||
| Yoshikawa S | 2007 | 5 | 0/4/1 | 54.5 ± 12 | 2790.4 ± 2607.6 U/ml |
| 44 | NA | NA | 265.8 ± 136.2 U/ml |
(*: In this study, the case group was AHP and the control group was CHP.)
NA, not applicable; KL-6, Krebs von den Lungen 6; HP, Hypersensitivity pneumonitis; fHP, fibrotic Hypersensitivity pneumonitis; nfHP, non fibrotic Hypersensitivity pneumonitis; AHP, Acute Hypersensitivity pneumonitis; CHP, Chronic hypersensitivity pneumonitis.